购物车
- 全部删除
- 您的购物车当前为空
Allitinib (AST-1306) 是可口服的 EGFR 和 ErbB2不可逆抑制剂,IC50分别为 0.5 和 3 nM。它具有抗癌活性,抑制 ErbB4,IC50为 0.8 nM。
Allitinib (AST-1306) 是可口服的 EGFR 和 ErbB2不可逆抑制剂,IC50分别为 0.5 和 3 nM。它具有抗癌活性,抑制 ErbB4,IC50为 0.8 nM。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 477 | 现货 | |
5 mg | ¥ 1,160 | 现货 | |
10 mg | ¥ 1,860 | 现货 | |
25 mg | ¥ 3,390 | 现货 | |
50 mg | ¥ 4,850 | 现货 | |
100 mg | ¥ 6,730 | 现货 | |
500 mg | ¥ 13,500 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 1,350 | 现货 |
产品描述 | Allitinib (AST-1306) (AST-1306) has anti-cancer activity,and it is an irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. [1] |
靶点活性 | EGFR:0.5 nM, EGFR (L858R/T790M):12 nM, ERB4:0.8 nM, ErbB2:3 nM |
体外活性 | AST1306 (AST-1306; 0.19-6.25 μM; 72 hours) inhibit the growth of HIH3T3-EGFR T790M/L858R cells[1]. AST1306 (0.001-1.0 μM; 4 hours) is more than 3000-fold selective for ErbB family kinases over other kinase families[1]. AST1306 inhibits the activation of tyrosine kinases and downstream signaling pathways in A549 cells, Calu-3 cells and SK-OV-3 cells,and dose-dependently and markedly inhibits EGF-induced EGFR phosphorylation in A549 cells[1]. |
体内活性 | AST1306 (AST-1306; oral; 25-100 mg/kg) significantly inhibited tumor growth in SK-OV-3 and Calu-3 xenograft models[1]. |
别名 | AST-1306, ALS 1306 |
分子量 | 448.88 |
分子式 | C24H18ClFN4O2 |
CAS No. | 897383-62-9 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 55 mg/mL (122.53 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.